Application of Predictive Modeling in the Development of Amorphous Solid Dispersions

Effective modeling and simulation can reduce physical experimental requirements, ASD development risks, and time to market.

Formulators challenged by promising investigational drug candidates with high bioactivity but limited solubility increasingly find amorphous solid dispersions (ASDs) an attractive solution for enhancing bioavailability. The FDA approved nearly 50 drug products formulated as ASDs between 2012 and 2023.¹ However, identifying the optimum method of ASD preparation (eg, spray drying [SD] or hot-melt extrusion [HME]) and choosing the polymeric carrier, surfactant, and drug loading level can be challenging.

Related to this article

Anktiva, given with BCG, now approved for BCG-unresponsive high-grade papillary-only bladder cancer.

October 16th, 2026

Bladder Cancer: FDA Expands Anktiva Without a New Trial

The FDA expanded Anktiva to BCG-unresponsive papillary-only NMIBC using existing CIS trial data, a precedent with implications for development timelines and supply planning.

October 16th, 2026

PharmTech Weekly Roundup—October 16, 2026: Rare Diseases, CMC, and AI Accountability

AI accountability, faster FDA pathways, rare disease CMC review, and next-gen GLP-1 formulation lead this week’s PharmTech roundup.

AstraZeneca taps insitro’s AI to find new MASH and cardiomyopathy targets in a $40M upfront deal.

October 15th, 2026

MASH and Cardiomyopathy Targets: Why AstraZeneca Chose insitro’s AI

MASH and cardiomyopathy AI collaboration: AstraZeneca pays insitro $40M upfront for target discovery, then leads clinical development and CMC planning.

October 15th, 2026

First-in-Human Trial Speed: Why FDA Trails China

Boyang Wang, Immortal Dragons, discusses how the FDA’s Expedited IND Pilot must prove efficiency as sponsors chase the fastest route to valid first-in-human data.

October 15th, 2026

Rare Pediatric PRVs: Manufacturing Strategies for Expedited Approval, Part 1

Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about rare disease treatment development and navigating the FDA’s Rare Pediatric Disease Priority Review Voucher Program.

Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS) | © Tada Images - stock.adobe.com (521699065)

October 14th, 2026

FDA Rare Disease Framework Puts CMC Review in Scope

The FDA’s Rare Disease Framework Initiative brings risk-based CMC review and pre-approval inspections into scope for sponsors, CDMOs, and quality teams.

NVIDIA’s $250M compute donation backs UK agentic AI safety research relevant to GMP AI validation.

October 14th, 2026

NVIDIA’s $250M Agentic AI Safety Bet: What GMP Gains

NVIDIA’s $250M, five-year compute donation funds UK agentic AI safety research, with implications for how GMP teams validate and govern autonomous AI.

October 13th, 2026

Clinical Trial Delays: FDA’s Expedited IND Pilot vs China’s 818 Decree

Boyang Wang, Immortal Dragons, explains how FDA’s Expedited IND Pilot and research partners could speed serial steps to first-in-human trials compared to China’s 818 Decree.